This book compiles state-of-the-art statistical approaches to solving problems in clinical oncology, focusing on clinical trials in phases I, II, and III, as well as quality of life and economic analyses, and exploratory methods. Examines trial design treatment based on toxicity and survival! Featur
Handbook of Statistics in Clinical Oncology
โ Scribed by John Crowley, Antje Hoering
- Publisher
- Marcel Dekker
- Year
- 2001
- Tongue
- English
- Leaves
- 563
- Series
- Fluid Power and Control Series
- Edition
- illustrated edition
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
Southwest Oncology Group Statistical Center, Seattle, WA. Compendium of statistical approaches to the problems facing researchers. Focuses on cancer clinical trials, with a few contributions applying to observational studies. For statisticians working in cancer research and also oncologists. Expanded-outline format.
๐ SIMILAR VOLUMES
This book compiles state-of-the-art statistical approaches to solving problems in clinical oncology, focusing on clinical trials in phases I, II, and III, as well as quality of life and economic analyses, and exploratory methods. Examines trial design treatment based on toxicity and survival! Featur
Many new challenges have arisen in the area of oncology clinical trials. New cancer therapies are often based on cytostatic or targeted agents, which pose new challenges in the design and analysis of all phases of trials. The literature on adaptive trial designs and early stopping has been exploding
A compendium of cutting-edge statistical approaches to solving problems in clinical oncology, Handbook of Statistics in Clinical Oncology, Second Edition focuses on clinical trials in phases I, II, and III, proteomic and genomic studies, complementary outcomes and exploratory methods. Cancer Forum c
A compendium of cutting-edge statistical approaches to solving problems in clinical oncology, <b>Handbook of Statistics in Clinical Oncology, Second Edition</b> focuses on clinical trials in phases I, II, and III, proteomic and genomic studies, complementary outcomes and exploratory methods. <i>Canc